ARNA Share Price

Open 1.41 Change Price %
High 1.41 1 Day 0.00 0.00
Low 1.39 1 Week 0.10 7.75
Close 1.39 1 Month -0.10 -6.71
Volume 1623504 1 Year -0.40 -22.35
52 Week High 2.15
52 Week Low 1.20
ARNA Important Levels
Resistance 2 1.41
Resistance 1 1.40
Pivot 1.40
Support 1 1.38
Support 2 1.37
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
SIRI 5.11 -1.73%
STX 42.01 -16.83%
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CMLS 0.28 21.74%
ZAZA 0.06 20.00%
CONN 17.50 18.24%
CONN 17.50 18.24%
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA)

ARNA Technical Analysis 4
As on 26th Apr 2017 ARNA Share Price closed @ 1.39 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.58 & Sell for SHORT-TERM with Stoploss of 1.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
ARNA Target for April
1st Target up-side 1.62
2nd Target up-side 1.73
3rd Target up-side 1.84
1st Target down-side 1.3
2nd Target down-side 1.19
3rd Target down-side 1.08
ARNA Other Details
Segment EQ
Market Capital 1647816448.00
Sector Healthcare
Industry Biotechnology
Offical website
ARNA Address
6154 Nancy Ridge Drive
San Diego, CA 92121
United States
Phone: 858-453-7200
Fax: 858-453-7210
ARNA Latest News
Interactive Technical Analysis Chart Arena Pharmaceuticals, Inc. ( ARNA NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Arena Pharmaceuticals, Inc.
ARNA Business Profile
Arena Pharmaceuticals, Inc. (Arena), incorporated on April 14, 1997, is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. The Company’s oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension, which is in Phase I; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases, which has completed single- and multiple-ascending dose Phase I trials; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases, and APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain, which is in preclinical development. In June 2012, the United States Food and Drug Administration (FDA) approved its internally discovered drug, BELVIQ, for chronic weight management in adults who are overweight with comorbidity or obese. The Company’s research and development programs also include GPR119 and earlier-stage programs that span several therapeutic areas. The three trials included in its BELVIQ Phase III development program are BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and Lorcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), which enrolled approximately 7,794. In October 2012, the Company initiated a Phase I multiple dose clinical trial of APD811. In April 2013, the Company initiated a randomized, double-blind and placebo-controlled Phase I clinical trial of APD334. APD371 is the Company’s lead product, which is under preclinical development. GPR119 is a pharmaceutical target for discovering orally available small molecule agonists for the treatment of type 2 diabetes. GPR119 is expressed in beta cells, which are located in the pancreas and responsible for secreting insulin in response to increases in blood glucose.